Relationship between ¹²³l-metaiodobenzylguanidine (¹²³l-MIBG) imaging findings and outcome in patients with neuroblastoma at the Red Cross War Memorial Children's Hospital

Simple item page
dc.contributor.advisorBrink, Anitaen_ZA
dc.contributor.advisorMann, Michael Den_ZA
dc.contributor.authorAmoako, Yaw Ampemen_ZA
dc.date.accessioned2018-02-09T07:22:12Z
dc.date.available2018-02-09T07:22:12Z
dc.date.issued2017en_ZA
dc.description.abstractBackground: In neuroblastoma, the presence of distant metastases is associated with a poor prognosis. Aim: To assess the relationship between the findings on ¹²³I-MIBG scan and outcome in patients with neuroblastoma at the Red Cross War Memorial Children's Hospital (RCWMCH). Methods: A single observer reviewed the ¹²³I-MIBG scans and clinical data of patients who had a histologically confirmed diagnosis of neuroblastoma and a baseline ¹²³I-MIBG scan and at least one follow up scan after chemotherapy cycles 4 or 7 between January 2001 and May 2015. Follow up extended to June 2016. Disease burden was assessed using the Curie scoring (CS) method. Results: Thirty four stage 4 patients were included in the analysis. Twenty nine (85%) were older than 12 months, with a median age at diagnosis of 32.5 months (range 6 - 93 months). 62% of primary tumours were located in the adrenal gland and half were NMYC amplified. Twenty (59%) patients died, 90% of deaths occurring in patients older than 12 months. No deaths were recorded in the 13 months after recruitment ended. The baseline CS did not predict outcome (alive or dead) or duration of survival. Patients with CS >2 (n = 5) on the cycle 4 scan had a median survival of 19.5 months compared with 29 months for those with a score ≤ 2 (n = 17, p = 0.88). Patients with a CS > 2 on the cycle 7 scan (n = 7) had a median survival of 28 months compared with 35 months for those with CS ≤ 2 (n = 14, p = 0.93). There was no relationship between the magnitude of the decrease in CS between the baseline and post cycle 4 or 7 scans and outcome. Conclusion: In these 34 high risk patients, the baseline CS and CS at cycle 4 or cycle 7 were not significantly indicative of survival. This is similar to other studies that did not find the pre-treatment score or the post treatment MIBG scan to be a predictor of outcome.en_ZA
dc.identifier.apacitationAmoako, Y. A. (2017). <i>Relationship between ¹²³l-metaiodobenzylguanidine (¹²³l-MIBG) imaging findings and outcome in patients with neuroblastoma at the Red Cross War Memorial Children's Hospital</i>. (Thesis). University of Cape Town ,Faculty of Health Sciences ,Division of Nuclear Medicine. Retrieved from http://hdl.handle.net/11427/27433en_ZA
dc.identifier.chicagocitationAmoako, Yaw Ampem. <i>"Relationship between ¹²³l-metaiodobenzylguanidine (¹²³l-MIBG) imaging findings and outcome in patients with neuroblastoma at the Red Cross War Memorial Children's Hospital."</i> Thesis., University of Cape Town ,Faculty of Health Sciences ,Division of Nuclear Medicine, 2017. http://hdl.handle.net/11427/27433en_ZA
dc.identifier.citationAmoako, Y. 2017. Relationship between ¹²³l-metaiodobenzylguanidine (¹²³l-MIBG) imaging findings and outcome in patients with neuroblastoma at the Red Cross War Memorial Children's Hospital. University of Cape Town.en_ZA
dc.identifier.ris TY - Thesis / Dissertation AU - Amoako, Yaw Ampem AB - Background: In neuroblastoma, the presence of distant metastases is associated with a poor prognosis. Aim: To assess the relationship between the findings on ¹²³I-MIBG scan and outcome in patients with neuroblastoma at the Red Cross War Memorial Children's Hospital (RCWMCH). Methods: A single observer reviewed the ¹²³I-MIBG scans and clinical data of patients who had a histologically confirmed diagnosis of neuroblastoma and a baseline ¹²³I-MIBG scan and at least one follow up scan after chemotherapy cycles 4 or 7 between January 2001 and May 2015. Follow up extended to June 2016. Disease burden was assessed using the Curie scoring (CS) method. Results: Thirty four stage 4 patients were included in the analysis. Twenty nine (85%) were older than 12 months, with a median age at diagnosis of 32.5 months (range 6 - 93 months). 62% of primary tumours were located in the adrenal gland and half were NMYC amplified. Twenty (59%) patients died, 90% of deaths occurring in patients older than 12 months. No deaths were recorded in the 13 months after recruitment ended. The baseline CS did not predict outcome (alive or dead) or duration of survival. Patients with CS >2 (n = 5) on the cycle 4 scan had a median survival of 19.5 months compared with 29 months for those with a score ≤ 2 (n = 17, p = 0.88). Patients with a CS > 2 on the cycle 7 scan (n = 7) had a median survival of 28 months compared with 35 months for those with CS ≤ 2 (n = 14, p = 0.93). There was no relationship between the magnitude of the decrease in CS between the baseline and post cycle 4 or 7 scans and outcome. Conclusion: In these 34 high risk patients, the baseline CS and CS at cycle 4 or cycle 7 were not significantly indicative of survival. This is similar to other studies that did not find the pre-treatment score or the post treatment MIBG scan to be a predictor of outcome. DA - 2017 DB - OpenUCT DP - University of Cape Town LK - https://open.uct.ac.za PB - University of Cape Town PY - 2017 T1 - Relationship between ¹²³l-metaiodobenzylguanidine (¹²³l-MIBG) imaging findings and outcome in patients with neuroblastoma at the Red Cross War Memorial Children's Hospital TI - Relationship between ¹²³l-metaiodobenzylguanidine (¹²³l-MIBG) imaging findings and outcome in patients with neuroblastoma at the Red Cross War Memorial Children's Hospital UR - http://hdl.handle.net/11427/27433 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/27433
dc.identifier.vancouvercitationAmoako YA. Relationship between ¹²³l-metaiodobenzylguanidine (¹²³l-MIBG) imaging findings and outcome in patients with neuroblastoma at the Red Cross War Memorial Children's Hospital. [Thesis]. University of Cape Town ,Faculty of Health Sciences ,Division of Nuclear Medicine, 2017 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/27433en_ZA
dc.language.isoengen_ZA
dc.publisher.departmentDivision of Nuclear Medicineen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.subject.otherNuclear Medicineen_ZA
dc.titleRelationship between ¹²³l-metaiodobenzylguanidine (¹²³l-MIBG) imaging findings and outcome in patients with neuroblastoma at the Red Cross War Memorial Children's Hospitalen_ZA
dc.typeMaster Thesis
dc.type.qualificationlevelMasters
dc.type.qualificationnameMMeden_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceThesisen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
thesis_hsf_2017_amoako_yaw_ampem (1).pdf
Size:
2.58 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Masters